Aerin Medical Marks RhinAer Treatment Milestone

More than 200,000 patients have been treated with Aerin Medical Inc.’s RhinAer and VivAer temperature- and impedance-controlled radiofrequency technologies, the company announced.

This milestone reflects the growing real-world impact of RhinAer and VivAer, as an increasing number of physicians integrate these solutions into their chronic rhinitis (CR) and nasal airway obstruction (NAO) treatment protocols, according to the company. Clinical studies evaluating Aerin products have enrolled nearly 1,000 patients globally, contributing to evidence demonstrating statistically significant and durable symptom improvement.

This progress reflects continued innovation, a strong foundation of clinical evidence, and a commitment to expanding patient access, supporting Aerin’s leadership in minimally invasive procedures for patients with CR and NAO, Aerin Medical bigwigs claim.

“We celebrate this milestone alongside the otolaryngologists who have made it possible,” Aerin Medical President/CEO Matt Brokaw said. “Our close partnership with physicians enables the design of technology and the completion of clinical studies reflected in more than 40 peer-reviewed publications. That collaboration is now translating into expanding access to the treatment of appropriate patients. Patients and physicians are at the center of all that we do, and this milestone is particularly gratifying and motivating.”

VivAer is a minimally invasive technology that uses patented, temperature- and impedance-controlled radiofrequency energy and is clinically demonstrated to provide long-term relief from nasal obstruction. VivAer features a thin, wand-like stylus that attaches to an Aerin console. The stylus is inserted through the nostril to gently remodel the nasal tissue and improve airflow. VivAer does not involve cutting, nasal tissue or bone removal, or the use of an implant. The procedure is performed in-office under local anesthesia, with no incisions and minimal downtime. The VivAer Stylus received CE Mark certification in 2016 and U.S. Food and Drug Administration (FDA) 510(k) clearance in December 2017.

RhinAer is a minimally invasive technology that uses patented, temperature- and impedance-controlled radiofrequency energy and is clinically demonstrated to provide long-term relief from chronic rhinitis. RhinAer features a thin, wand-like stylus that attaches to an Aerin console. The stylus is inserted through the nostril to deliver precise therapeutic benefits to the posterior nasal nerve (PNN) and soft tissue, while sparing surrounding tissues. RhinAer directly disrupts the PNN that triggers excessive mucus production, treating an underlying cause of chronic rhinitis. RhinAer provides ENT physicians with a comprehensive solution for treating chronic rhinitis, addressing sources of rhinorrhea and congestion. The procedure can be performed with a local anesthetic during an office visit, with no incisions and minimal downtime. RhinAer received FDA 510(k) clearance in December 2019 and CE Mark certification in 2020.

Aerin Medical is a privately held, venture-backed company headquartered in Mountain View, Calif. It strives to expand access to relief for patients suffering from chronic ENT conditions. The company’s products, VivAer for nasal airway obstruction and RhinAer for chronic rhinitis, leverage Aerin’s proprietary temperature- and impedance-controlled technology, which allows ENT physicians to reliably improve patients’ symptoms with unique technologies that are appealing alternatives to invasive surgery.